Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Phase 2

Completed

• Conditions: Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Small Lymphocytic Lymphoma; Intraocular Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Testicular Lymphoma; Waldenström Macroglobulinemia
• Interventions: Biological: oblimersen sodium; Biological: rituximab; Other: laboratory biomarker analysis

• Registration Number: NCT00054639
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

The goal of this clinical research study is to learn if the combination of oblimersen sodium and rituximab can help to shrink or slow the growth of the tumor in patients with B-cell non-Hodgkin's lymphoma who have not responded to earlier treatment. Oblimersen Sodium is an investigational drug. The safety of this combination treatment will also be studied

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the therapeutic efficacy and toxicity of G3139 (oblimersen sodium) and Rituximab in patients with recurrent B-cell NHL.

SECONDARY OBJECTIVES:

I. To determine the effect of G3139 and Rituximab on the level of Bcl-2 expression.

II. The secondary objective of this study is to evaluate the effect of G3139 and Rituximab on Bcl-2 protein gene expression.

OUTLINE:

Patients receive oblimersen sodium intravenously (IV) continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.

After completion of study treatment, patients are followed up every 3 months.

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2003-02-05
• Study First Submitted QC: 2003-02-05
• Study First Posted: 2003-02-06
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Results First Submitted: 2011-01-24
• Results First Submitted QC: 2011-01-24
• Results First Posted: 2011-02-21
• Status Verified: 2013-03
• Last Update Submitted: 2014-05-13
• Last Update Posted: 2014-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Must have recurrent B-cell NHL and measurable disease
• No anti-lymphoma therapy within the past 4 weeks
• Must have a good performance status (less than or equal to 2 Zubrod, greater than or equal to 60 Karnofsky)
• Absolute neutrophil count (ANC) greater than or equal to 1,000
• Platelets greater than or equal to 75,000
• Hemoglobin greater than or equal to 10 g/dL
• Bilirubin less than or equal to 1.5 mg/dL
• Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT) less than or equal to 2 times upper limit of laboratory normals
• Alkaline phosphatase less than or equal to 2 times upper limit of laboratory normals
• Serum creatinine less than or equal to 1.8 mg/dL
• Must sign a consent form, and must have a life expectancy of greater than 12 weeks
• No more than 3 prior chemotherapy regimens
• Patients who are either Rituximab naive, have previously responded to Rituximab, or are refractory to Rituximab used alone or in combination with chemotherapy

Exclusion Criteria

• Human immunodeficiency virus (HIV) positive
• Active infection or history of opportunistic infections
• Pregnant women and women of childbearing age who are not practicing adequate contraception; men who are not willing to use an effective method of contraception
• History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for 5 or more years)
• Active autoimmune disease
• Other significant medical diseases
• Patients with chronic lymphocytic leukemia (CLL)
• Prior exposure to G3139

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (oblimersen sodium and monoclonal antibody therapy)	rituximab	Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
Treatment (oblimersen sodium and monoclonal antibody therapy)	oblimersen sodium	Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
Treatment (oblimersen sodium and monoclonal antibody therapy)	laboratory biomarker analysis	Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.

Primary Outcome Measures

Name	Time	Method
Number of Patients With Objective Response	2 months following study treatment	Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment

Trial Locations

Locations (1)

M D Anderson Cancer Center; 🇺🇸 Houston, Texas, United States